+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Migraine Drugs Market by Type, Route of Administration, and Distribution Channel - Global Opportunity Analysis and Industry Forecast, 2018-2025

  • ID: 4612778
  • Report
  • Region: Global
  • 225 pages
  • Allied Analytics LLP
1 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • Endo International Plc.
  • Impax Laboratories
  • Merck & Co.
  • Pfizer Inc.
  • MORE
Migraine is characterized by a recurrent throbbing headache, which usually lasts from four hours to three days. This occurs on one side of the head, but may spread to both sides. It is often accompanied by vomiting, sensitivity to light or sound, nausea, and disturbed vision in some cases. Migraine is sometimes preceded by an aura that is followed by fatigue. The global migraine drugs market was valued at $1,713 million in 2017, and is expected to reach $2,190 million by 2025, growing at a CAGR of 3.1% from 2018 to 2025.

Rise in awareness among patients for migraine treatment & prevention, rapid increase in female population, and surge in prevalence of migraine drive the growth of the global migraine drugs market. However, side effects associated with migraine drugs limit the market growth. On the contrary, growth opportunities in the developing nations and emerging new therapies for migraine treatment are expected to present opportunities for the market growth during the forecast period.

The report segments the migraine drugs market based on type, route of administration, distribution channel, and region. Based on type, the market is bifurcated into abortive medicine and preventive medicine. Depending on route of administration, it is fragmented into oral, injection, and others. By distribution channel, it is categorized into hospital-based Pharmacies, retail Pharmacies, and online Pharmacies. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS

This report entails a detailed quantitative analysis of the overall market trends from 2017 to 2025 to identify the prevailing opportunities along with strategic assessment of the global migraine drugs market.
Market size and estimations are based on comprehensive analysis of the applications and developments in the industry.
An in-depth analysis based on region is provided to understand the regional market and facilitate the strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Type

Abortive Medicine
Triptans (Serotonin Receptor Agonists)
Ergotamine Derivative
Other
Preventive Medicine
Anticonvulsant
Antidepressant
Beta Blocker
Others

By Route of Administration

Oral
Injection
Others

By Distribution Channel

Hospital-based Pharmacies
Retail Pharmacies
Online Pharmacies

By region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

The list of key players operating in this market includes:

Abbott Laboratories
Allergan Plc.
AstraZeneca
Eisai Co., Ltd.
Endo International Plc.
GlaxoSmithKline Plc.
Impax Laboratories
Johnson & Johnson
Merck & Co.
Pfizer Inc.

The OTHER PLAYERS included in the value chain analysis (and not included in the report) include:

Novartis International AG
Teva Pharmaceutical Industries Limited
Sanofi SA
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • Endo International Plc.
  • Impax Laboratories
  • Merck & Co.
  • Pfizer Inc.
  • MORE
CHAPTER 1: INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.3.1. List of players profiled in the report
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2016-2018
3.2.3. Market share analysis, 2017
3.3. MARKET DYNAMICS
3.3.1. Drivers
3.3.1.1. Increase in prevalence of migraine
3.3.1.2. Growth in female population
3.3.1.3. Rise in awareness among patients towards migraine treatment & prevention
3.3.2. Restraints
3.3.2.1. Side effects of migraine drugs
3.3.3. Opportunities
3.3.3.1. Emerging migraine therapies
3.3.3.2. Growth opportunities in the emerging economies
3.3.4. Impact analyses

CHAPTER 4: MIGRAINE DRUGS MARKET, BY TYPE
4.1. Overview
4.2. Abortive medicines
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by type
4.2.2.1. Triptans
4.2.2.1.1. Market size and forecast
4.2.2.2. Ergotamine derivatives
4.2.2.2.1. Market size and forecast
4.2.2.3. Other abortive medicines
4.2.2.3.1. Market size and forecast
4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country
4.3. Preventive medicines
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by type
4.3.2.1. Anticonvulsants
4.3.2.1.1. Market size and forecast
4.3.2.2. Antidepressants
4.3.2.2.1. Market size and forecast
4.3.2.3. Beta blockers
4.3.2.3.1. Market size and forecast
4.3.2.4. Other preventive medicines
4.3.2.4.1. Market size and forecast
4.3.3. Market size and forecast, by region
4.3.4. Market analysis, by country

CHAPTER 5: MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Injection
5.3.1. Market size and forecast, region
5.3.2. Market analysis, by country
5.4. Other routes
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

CHAPTER 6: MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Retail pharmacies
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Hospital pharmacies
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Online pharmacies
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country

CHAPTER 7: MIGRAINE DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. migraine drugs market, by type
7.2.2.1.2. U.S. migraine drugs market, by route of administration
7.2.2.1.3. U.S. migraine drugs market, by distribution channel
7.2.2.2. Canada
7.2.2.2.1. Canada migraine drugs market, by type
7.2.2.2.2. Canada migraine drugs market, by route of administration
7.2.2.2.3. Canada migraine drugs market, by distribution channel
7.2.2.3. Mexico
7.2.2.3.1. Mexico migraine drugs market, by type
7.2.2.3.2. Mexico migraine drugs market, by route of administration
7.2.2.3.3. Mexico migraine drugs market, by distribution channel
7.2.3. North America migraine drugs market, by type
7.2.4. North America migraine drugs market, by route of administration
7.2.5. North America migraine drugs market, by distribution channel
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Germany migraine drugs market, by type
7.3.2.1.2. Germany migraine drugs market, by route of administration
7.3.2.1.3. Germany migraine drugs market, by distribution channel
7.3.2.2. France
7.3.2.2.1. France migraine drugs market, by type
7.3.2.2.2. France migraine drugs market, by route of administration
7.3.2.2.3. France migraine drugs market, by distribution channel
7.3.2.3. UK
7.3.2.3.1. UK migraine drugs market, by type
7.3.2.3.2. UK migraine drugs market, by route of administration
7.3.2.3.3. UK migraine drugs market, by distribution channel
7.3.2.4. Italy
7.3.2.4.1. Italy migraine drugs market, by type
7.3.2.4.2. Italy migraine drugs market, by route of administration
7.3.2.4.3. Italy migraine drugs market, by distribution channel
7.3.2.5. Spain
7.3.2.5.1. Spain migraine drugs market, by type
7.3.2.5.2. Spain migraine drugs market, by route of administration
7.3.2.5.3. Spain migraine drugs market, by distribution channel
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe migraine drugs market, by type
7.3.2.6.2. Rest of Europe migraine drugs market, by route of administration
7.3.2.6.3. Rest of Europe migraine drugs market, by distribution channel
7.3.3. Europe migraine drugs market, by type
7.3.4. Europe migraine drugs market, by route of administration
7.3.5. Europe migraine drugs market, by distribution channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan
7.4.2.1.1. Japan migraine drugs market, by type
7.4.2.1.2. Japan migraine drugs market, by route of administration
7.4.2.1.3. Japan migraine drugs market, by distribution channel
7.4.2.2. China
7.4.2.2.1. China migraine drugs market, by type
7.4.2.2.2. China migraine drugs market, by route of administration
7.4.2.2.3. China migraine drugs market, by distribution channel
7.4.2.3. India
7.4.2.3.1. India migraine drugs market, by type
7.4.2.3.2. India migraine drugs market, by route of administration
7.4.2.3.3. India migraine drugs market, by distribution channel
7.4.2.4. Australia
7.4.2.4.1. Australia migraine drugs market, by type
7.4.2.4.2. Australia migraine drugs market, by route of administration
7.4.2.4.3. Australia migraine drugs market, by distribution channel
7.4.2.5. South Korea
7.4.2.5.1. South Korea migraine drugs market, by type
7.4.2.5.2. South Korea migraine drugs market, by route of administration
7.4.2.5.3. South Korea migraine drugs market, by distribution channel
7.4.2.6. Rest of Asia-Pacific
7.4.2.6.1. Rest of Asia-Pacific migraine drugs market, by type
7.4.2.6.2. Rest of Asia-Pacific migraine drugs market, by route of administration
7.4.2.6.3. Rest of Asia-Pacific migraine drugs market, by distribution channel
7.4.3. Asia-Pacific migraine drugs market, by type
7.4.4. Asia-Pacific migraine drugs market, by route of administration
7.4.5. Asia-Pacific migraine drugs market, by distribution channel
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil
7.5.2.1.1. Brazil migraine drugs market, by type
7.5.2.1.2. Brazil migraine drugs market, by route of administration
7.5.2.1.3. Brazil migraine drugs market, by distribution channel
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia migraine drugs market, by type
7.5.2.2.2. Saudi Arabia migraine drugs market, by route of administration
7.5.2.2.3. Saudi Arabia migraine drugs market, by distribution channel
7.5.2.3. South Africa
7.5.2.3.1. South Africa migraine drugs market, by type
7.5.2.3.2. South Africa migraine drugs market, by route of administration
7.5.2.3.3. South Africa migraine drugs market, by distribution channel
7.5.2.4. Rest of LAMEA
7.5.2.4.1. Rest of LAMEA migraine drugs market, by type
7.5.2.4.2. Rest of LAMEA migraine drugs market, by route of administration
7.5.2.4.3. Rest of LAMEA migraine drugs market, by distribution channel
7.5.3. LAMEA migraine drugs market, by type
7.5.4. LAMEA migraine drugs market, by route of administration
7.5.5. LAMEA migraine drugs market, by distribution channel

CHAPTER 8: COMPANY PROFILES
8.1. Abbott Laboratories
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product Portfolio
8.1.5. Business performance
8.2. AbbVie Inc.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product Portfolio
8.2.5. Business performance
8.3. Allergan Plc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product Portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. AstraZeneca PLC
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product Portfolio
8.4.5. Business performance
8.5. Eisai Co., Ltd.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. Endo International Plc.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product Portfolio
8.6.5. Business performance
8.7. GlaxoSmithKline Plc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product Portfolio
8.7.5. Business performance
8.8. Johnson & Johnson
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product Portfolio
8.8.5. Business performance
8.9. Merck & Co., Inc.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product Portfolio
8.9.5. Business performance
8.10. Pfizer Inc.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product Portfolio
8.10.5. Business performance
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • Endo International Plc.
  • Impax Laboratories
  • Merck & Co.
  • Pfizer Inc.
  • MORE
According to a new report, titled, Migraine Drugs by Type, Route of Administration, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2018-2025, the market was valued at $1,713 million in 2017, and is expected to reach $2,190 million by 2025, growing at a CAGR of 3.1% from 2018 to 2025. North America is anticipated to be the highest revenue contributor throughout the forecast period.

Migraine is characterized by a recurrent throbbing headache, which affects only one side of the head. It is accompanied by vomiting, usea, and even disturbed vision in some cases.

Increase in prevalence of migraine, rapid rise in female population, and surge in awareness among patients for migraine treatment & prevention drive the growth of the global migraine drugs market. However, side effects of migraine drugs are expected to limit the market growth. Conversely, emerging new therapies/drugs for migraine treatment and growth opportunities in the emerging tions are expected to present opportunities for the market growth during the forecast period.

By type, abortive medicines accounted for more than three-fourths share of the global migraine drugs market in 2017. Furthermore, by route of administration, the oral segment is anticipated to grow at the highest rate of 3.4% during the forecast period.

Key Findings of the Migraine Drugs Market:

North America occupied two-fifths share of the global migraine drugs market.
Oral is anticipated to grow with the highest CAGR throughout the forecast period.
Europe is anticipated to occupy more than one-fourth market share of the global migraine drugs market by 2025.
Asia-Pacific is anticipated to grow at the highest rate during the Analysis period, followed by LAMEA.

North America was the leading revenue contributor to the global market in 2017, owing to surge in demand for better healthcare along with effective government reforms for awareness towards migraine & its prevention. However, Asia-Pacific is expected to grow at the highest CAGR of 4.4% from 2018 to 2025, due to improvements in healthcare infrastructure and rise in demand for better healthcare facilities.

The report provides an extensive competitive Analysis and profiles of the key market players such as Abbott Laboratories, Allergan Plc., AstraZeneca, Eisai Co., Ltd., Endo Intertiol Plc., GlaxoSmithKline Plc., Impax Laboratories, Johnson & Johnson, Merck & Co., and Pfizer Inc. The other players in the value chain (not included in the report) include Novartis Intertiol AG, Teva Pharmaceutical Industries Limited, and Sanofi SA.
Note: Product cover images may vary from those shown
5 of 5
  • Abbott Laboratories
  • Allergan Plc.
  • AstraZeneca
  • Eisai Co., Ltd.
  • Endo International Plc.
  • GlaxoSmithKline Plc.
  • Impax Laboratories
  • Johnson & Johnson
  • Merck & Co.
  • Pfizer Inc.
  • Novartis International AG
  • Teva Pharmaceutical Industries Limited
  • Sanofi SA
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4612778
Adroll
adroll